Bajorin DF et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 2021;384(22):2102-14. Abstract
Balar AV et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): An open-label, single-arm, multicentre, phase 2 study. Lancet Oncology 2021;22(7):919-30. Abstract
Black PC et al. Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816). ASCO 2021;Abstract 4541.
Boorjian SA, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: A single-arm, open-label, repeat-dose clinical trial. Lancet Oncol 2021;22(1):107-17. Abstract
Chamie K et al. Phase 2/3 clinical results of IL-15RAFC superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in-situ (cis) patients. AUA 2021;Abstract PD09-05.
Daneshmand S et al. The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: A phase I trial. Urol Oncol 2022;[Online ahead of print]. Abstract
Friedlander TW et al. Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC). ASCO 2021;Abstract 4528.
Galsky MD et al. Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trasutuzumab deruxtecan (T-DXd) with nivolumab in patients (pts) with HER2-expressing urothelial carcinoma (UC). ASCO GU 2021;Abstract 438.
Guercio BJ et al. Large cell neuroendocrine carcinoma of the urothelial tract (LNEC): The MSKCC experience. ASCO GU 2022;Abstract 4526.
Li R et al. CORE1: Phase 2, single arm study of CG0070 combined with pembrolizumab in patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG). AACR 2022;Abstract CT036.
Pal SK et al. Adjuvant chemotherapy for bladder cancer: Using population-based data to fill a void of prospective evidence. J Clin Oncol 2016;34(8):777-9. Abstract
Powles T et al. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial. ASCO GU 2022;Abstract 487.
Powles T et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 2021;595(7867):432-7. Abstract
Powles T et al. Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma. ASCO GU;Abstract 393.
Steinberg RL et al. Multi-institutional evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer. J Urol 2020;203(5):902-9. Abstract
Tagawa ST et al. TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol 2021;39(22):2474-85. Abstract
Vuky J et al. Long-term outcomes in KEYNOTE-052: Phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. J Clin Oncol 2020;38(23):2658-66. Abstract